Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions
European Journal of Haematology · 2025-03 · 114 (3) · 386-399
DOI: 10.1111/ejh.14353 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 27.11.2024. Verfasst von Caterina Labanca und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple‐ and penta‐refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs). Administered following a step‐up dosing phase to manage cytokine release syndrome (CRS), talquetamab demonstrated a high overall response rate (ORR) of approximately 70%, including in patients previously treated with T‐cell redirecting therapies. Its safety profile is consistent with other BsAbs, with hematologic adverse events such as anemia and neutropenia commonly reported, alongside unique on‐target off‐tumor toxicities like dysgeusia and skin‐related events. Infections were less frequent compared to other BsAbs. The optimal sequencing of talquetamab and other therapies, including CAR‐T cell treatments, remains an area of active research, as resistance to anti‐BCMA therapies presents ongoing clinical challenges. Current trials are exploring the use of talquetamab in combination therapies, as well as therapeutic strategies post‐treating progression. The real‐world data further support talquetamab's efficacy, making it a valuable addition to the RRMM treatment landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
- Laboratorio di Ricerca Traslazionale Azienda USL-IRCSS Reggio Emilia, Emilia-Romagna, Italy.
- Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.
- Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Fortunato Morabito, Massimo Gentile
Zitieren
APA
Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., & Gentile, M. (2025). Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. European Journal of Haematology, 114(3), 386-399. https://doi.org/10.1111/ejh.14353
Vancouver
Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Lucia E, et al. Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. European Journal of Haematology. 2025;114(3):386-399. doi:10.1111/ejh.14353
BibTeX
@article{Labanca2025,
author = {Labanca, Caterina and Martino, Enrica Antonia and Vigna, Ernesto and Bruzzese, Antonella and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Puccio, Noemi and Neri, Antonino and Morabito, Fortunato and Gentile, Massimo},
title = {Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions},
journal = {European Journal of Haematology},
year = {2025},
volume = {114},
number = {3},
pages = {386--399},
doi = {10.1111/ejh.14353}
}
EUVIMED